Loading…
Loading…
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference being held at the New York Marriott Marquis in New York, NY.
Frazier Life Sciences Management L.P. raised its stake in shares of Erasca, Inc. (NASDAQ: ERAS) by 1.2% during the undefined quarter, according to the company in its most recent filing with the SEC. The firm owned 24,975,188 shares of the company's stock after purchasing an additional 300,000 shares during the quarter. Erasca accounts
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. (NASDAQ: ERAS) against certain of its officers and directors for alleged breaches of fiduciary duty.
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS).
New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.
BlackRock Inc. acquired a new position in Erasca, Inc. (NASDAQ: ERAS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 21,154,146 shares of the company's stock, valued at approximately $387,544,000. BlackRock Inc. owned approximately 6.80% of Erasca at
The Alger Mid Cap 40 ETF outperformed the Russell Midcap Growth Index during the second quarter of 2026. Astera Labs, Nebius Group, and Western Digital Corporation were among the top contributors to performance. Insmed Incorporated, IREN Limited, and Erasca, Inc. were among the top detractors from performance.
Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially registration-enabling trials planned across pancreatic and lung cancers Additional Phase 1 monotherapy and combination data expected in H1 2027 SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile.